Company Performance Metrics
Todd Brady: Director- John T. Henderson: Chairman
Asmacure is a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases.
The company’s lead compound, ASM-024, has a novel multi-functional mechanism of action with nicotinic and muscarinic effects.
ASM-024 has demonstrated the capabilities of anti-inflammation, bronchoprotection, and smooth muscle relaxation in pre-clinical asthma models.
Administered as a solution for nebulization in asthma patients, ASM-024 demonstrated clinical proof of concept in a phase 2 trial with significant effects on FEV1 and methacholine PC20. Asmacure has advanced ASM-024 into the clinic for the treatment of moderate asthma and COPD with a dry powder for inhalation (DPI) formulation. The DPI is a preferred dosage form for many patients and should allow ASM-024 to be delivered with greater lung deposition yielding the potential for a lower and more optimal dose.
Asmacure was founded by Dr. Yvon Cormier, a noted pulmonologist, and Dr Evelyne Israel-Assayag in 2002 and is based in Quebec City, Quebec, Canada.
